Avantor $AVTR claimed strength in biotech and life sciences but behind the beakers, they allegedly masked shrinking margins, lost key clients, and overstated growth. In this episode of Sue Wall Street, we break down the class action accusing Avantor of misleading investors, inflating valuations, and triggering a 25% stock slide. If you're into biotech markets, investor rights, or corporate accountability, don’t miss this one.